Cancer Research Investment in Canada, 2018 - PowerPoint Presentation

1. Cancer Research Investment in Canada, 2018

2. TopicSlidesBackground3, 4, 5Methodology6, 7, 8, 9, 10, 11Overall Investment Highlights12, 13, 14, 15, 16, 17, 18Areas of Science/CSO Highlights19, 20, 21Cancer Sites Highlights22, 23, 24Funding Mechanisms - Highlights25, 26, 27Operating Grants28, 29, 30Trainee Awards31, 32, 33Career Awards34, 35Equipment/infrastructure grants and Research Support Fund36, 37, 38Further information39, 40Slide Index2This slide deck is intended as a companion to the report, Cancer Research Investment in Canada, 2018 and presents different graphs and analyses to complement those in the report.

3. The CCRA is an alliance of organizations that collectively fund most of the cancer research conducted in Canada – research that will lead to better ways to prevent, diagnose, and treat cancer and improve survivor outcomes. Members include federal research funding programs/agencies, provincial research agencies, provincial cancer care agencies, cancer charities, and other voluntary associations. Member are motivated by the belief that, through effective collaboration, Canadian cancer research funding organizations can maximize their collective impact on cancer control and accelerate discovery for the ultimate benefit of Canadians affected by cancer.The Executive Office is supported by the Canadian Partnership Against Cancer, funded by Health Canada to work with Canada’s cancer community to implement the Canadian Strategy for Cancer Control to reduce the incidence of cancer, lessen the likelihood of Canadians dying from cancer, and enhance the quality of life of those affected by cancer. The Partnership is committed to enhancing the cancer research environment in Canada through its support of the CCRA and CCRA’s role in coordinating the cancer research funding system. As a member and funder of the CCRA, the Partnership collaborates with other member organizations to enable the strategy for cancer research in Canada. Introduction3

4. CCRA has grown from 23 members to over 30 members since its inception.The investment survey, the first joint activity of CCRA members, was first published in 2007 for data from year 2005 and included the research investments made by 19 funders. There are over 40 organizations tracked and 14 years of research funding data available for all funders.The CCRA has published two strategic plans: one for the period 2010-2014 and the other for 2015-2020. In addition, strategic frameworks have been published for prevention (2012), survivorship (2017), and palliative and end-of-life care (2017) research.The CCRA has convened five major research conferences – 2011 (Toronto), 2013 (Toronto), 2015 (Montréal), 2017 (Vancouver), and 2019 (Ottawa).The CCRA has supported clinical trials through its publication, Report on the State of Cancer Clinical Trials in Canada, (2011) which proposed the creation of the Canadian Cancer Clinical Trials Network (3CTN). 3CTN is now in its seventh year of operation.Since 2005…4

5. Members5Alberta Cancer FoundationAlberta InnovatesBrain Tumour Foundation of CanadaBreast Cancer Society of CanadaBC CancerC17 Research NetworkCanadian Association of Provincial Cancer AgenciesCanadian Association of Radiation OncologyCanadian Cancer Society*Canadian Institutes of Health ResearchCanadian Partnership Against CancerCancerCare ManitobaCancer Care OntarioCancer Research SocietyQuebec Breast Cancer FoundationFonds de recherche du Québec – SantéGenome CanadaThe Kidney Foundation of CanadaThe Leukemia and Lymphoma Society of CanadaMichael Smith Foundation for Health ResearchNational Research Council CanadaNew Brunswick Cancer NetworkNova Scotia Cancer Care ProgramOntario Institute for Cancer ResearchOvarian Cancer CanadaPancreatic Cancer CanadaPROCUREPublic Health Agency of CanadaResearch ManitobaSaskatchewan Cancer AgencySaskatchewan Health Research FoundationThe Terry Fox Research InstituteAffiliate member: BioCanRx*As of February 3, 2020, the Canadian Cancer Society and Prostate Cancer Canada have amalgamated.  

6. quantifies and qualifies cancer research investment in Canada by governmental and voluntary organizations in the form of an annual report for use by both Alliance members and the publicassists in the identification of significant gaps and potential opportunities in cancer researchhelps inform the activities of the pan-Canadian cancer research strategyCanadian Cancer Research Survey (CCRS)6

7. The Common Scientific Outline (CSO), used by the International Cancer Research Partnership (ICRP), is the principal classification framework. It is organized according to six broad areas of scientific interest: Biology, Etiology, Prevention, Early detection, diagnosis & prognosis, Treatment, and Cancer control, survivorship & outcomesWhere more than one CSO code is assigned to a given project, the budget is distributed equally among the codes.Two different coders work independently and code all projects, and then meet to discuss coding discrepancies and determine final codes.Project Classification – Areas of Science7

8. The International Statistical Classification of Diseases and Related Health Problems, (ICD-10), Version 2016, a global standard overseen by the World Health Organization, is used for site classification.Disease site coding is based on those sites identified by researchers in the project descriptions. Projects may be assigned more than one cancer site, and in those cases, budget allocations sum to 100% of the total.In those cases where a project is applicable to many cancer sites, the project is coded as “non-specific/all sites.”Project Classification – Cancer Sites8

9. Includes over 26,000 projects funded in calendar years 2005 to 2018 by 43 organizations/programs from the governmental and voluntary sectors in Canada (30 CCRA members, and 13 non-member organizations/programs). Projects were subjected to some form of peer review.Research investment was prorated and based on actual allocations over the 14 years and not financial commitments.The survey is estimated to cover most of research funding granted through formal, peer-reviewed funding programs and about 60-80% of all sources of research funding for Canadian cancer research.This slide deck highlights data for the 2018 year, but also provides comparisons within the last ten years, specifically years 2010 (10 years ago) and 2014 (five years ago).Report Scope9

10. Participating Organizations10GOVERNMENTCHARITIES/ASSOCIATIONSFederal Government AgenciesProvincial Cancer AgenciesProvincial Health Research OrganizationsCanada Excellence Research ChairsCanada Foundation for InnovationCanada Research Chairs ProgramCanadian Institutes of Health ResearchCanadian Partnership Against CancerGenome CanadaNational Research Council CanadaNatural Sciences and Engineering Research CouncilNetworks of Centres of ExcellencePublic Health Agency of CanadaSocial Sciences and Humanities Research CouncilCancerCare ManitobaCancer Care Nova ScotiaCancer Care Ontario [1]Saskatchewan Cancer AgencyAlberta Innovates Fonds de recherche du Québec - Santé Michael Smith Foundation for Health ResearchNew Brunswick Health Research FoundationNewfoundland and Labrador Centre for Applied Health ResearchNova Scotia Health Research Foundation [2]Ontario Institute for Cancer ResearchOntario Ministry of Economic Development, Job Creation and TradeResearch ManitobaSaskatchewan Health Research FoundationAlberta Cancer FoundationBeatrice Hunter Cancer Research InstituteBrain Tumour Foundation of CanadaBreast Cancer Society of CanadaC17 Research NetworkCanadian Association of Radiation OncologyCanadian Cancer SocietyCancer Research SocietyThe Cole FoundationThe Kidney Foundation of CanadaThe Leukemia & Lymphoma Society of CanadaOvarian Cancer CanadaPancreatic Cancer CanadaPediatric Oncology Group of OntarioPROCUREProstate Cancer Canada [3]Quebec Breast Cancer FoundationThe Terry Fox Research Institute[1] Cancer Care Ontario was dissolved in December 2019 and is now part of Ontario Health.[2] The operations of the former Nova Scotia Health Research Foundation became part of Research Nova Scotia in April 2019. Research Nova Scotia continued to offer the NSHRF programs until March 2020.[3] As of February 3, 2020, the Canadian Cancer Society and Prostate Cancer Canada amalgamated. The data in this presentation reflects the investments made by these individual organizations prior to this merger.

11. Projects funded by two or more organizations are represented in the investment amounts of the organizations that provided the funding.The budgets of projects were weighted on the basis of their cancer relevance. For projects that were not entirely focused on cancer, budgets were weighted between 5% and 80%.Analyses by geographic region were based solely on the institutional affiliation of the nominated principal investigator (PI).Reporting Conventions11

12. There was $491M invested in 2018 by the 43 organizations/programs tracked in the survey. This was a slight rise over 2017. The number of funded projects was considerably lower, which means higher amounts for fewer grants/awards. Programs/agencies of the federal government accounted for 51% of the investment in 2018.The largest investment was made by the Canadian Institutes of Health Research (CIHR) at $165M, which represented 33% of the total investment in 2018 and 66% of the total federal investment.The overall provincial investment, which includes the matching provincial investments in programs of the Canada Foundation of Innovation, was fairly constant for years 2014 to 2018, although there were fluctuations among individual organizations.A1. Overall Investment – Highlights for 201812

13. Among the charitable organizations/associations, the highest level of funding in 2018 was for the Canadian Cancer Society, which reflects the merger with the Canadian Breast Cancer Foundation that happened in 2017. The other leading research charity was The Terry Fox Research Institute. New federal monies will only see this investment increase in the coming years.Notably, the research investment by The Leukemia & Lymphoma Society of Canada more than doubled from 2014 to 2018.The research investment calculated on a per capita basis was highest for Canada’s most populous provinces – Ontario, Quebec and British Columbia. A2. Overall Investment – Highlights for 201813

14. 14

15. 15

16. 16

17. 17

18. 18

19. The 2018 investment by the six categories of the CSO was as follows:$115 M Biology$ 59 M Etiology $ 14 M Prevention $ 91 M Early detection, diagnosis & prognosis$170 M Treatment$ 42 M Cancer control, survivorship & outcomesThere was $38M more invested in Treatment research in 2018, compared with 2014. Investment in Biology research continued its downward trend – this investment peaked in 2007 at $195M. In 2018, it was $170M.B1. Areas of Science/CSO - Highlights19

20. 20

21. 21

22. Of the 2018 research investment, 57% was related to one or more cancer sites. The research investment related to brain cancers, leukemias, and ovarian cancers increased most substantially from 2010 to 2014 and again in 2018.Conversely, the investment in breast cancer research declined by $14M from 2010 to 2018.There remains a poor correlation between disease burden and site-specific research investment for some cancer sites.Burden of disease is just one way to assess the relative research investment.C1. Cancer Sites - Highlights22

23. 23

24. 24

25. The federal government sector investment, being the largest, also represented the largest portions of investment in operating grants, careers awards, trainee awards, and related support. Research-related support remained a small component of the overall funding mechanism mix, accounting for $0.7M in 2018.Investigator-initiated operating grants represented 47% of 2018 investment, re-bounding from previous years where there was growth in priority-driven investments.Nominated principal investigators working in Ontario, Canada’s largest province, received 54% of the total operating grant investment in 2018.D1. Funding Mechanisms - Highlights25

26. In 2018, $24M was invested trainee awards, which included all levels—undergraduate to post-doctorate.The trainee investment in Biology research showed the same declining trend as operating grants for the three years highlighted in this report. For all three years, proportionately more of the investment in trainee awards focused on Cancer control, survivorship and outcomes research.The investment in equipment/infrastructure in 2018 was higher than in 2014, although still lower than 2010. Institutional support, which for the purposes of the report was an estimate of the cancer component of the federal government’s Research Support Fund (RSF), was estimated to be $28M in 2018. The RSF assists Canadian postsecondary institutions with the costs associated with managing their research activities.D2. Funding Mechanisms- Highlights26

27. 27

28. 28

29. 29

30. 30

31. 31 2006 Investment  TYPE OF AWARD$%Number of ProjectsNumber of Projects Weighted at 100%Career/salary$18,718,46150339306Establishment$987,56533733Tier 1 CRC$11,574,0003110040Tier 2 CRC$5,383,0831411143Other chair$844,425275TOTAL$37,507,534100594427 2006 Investment  TYPE OF AWARD$%Number of ProjectsNumber of Projects Weighted at 100%Career/salary$18,718,46150339306Establishment$987,56533733Tier 1 CRC$11,574,0003110040Tier 2 CRC$5,383,0831411143Other chair$844,425275TOTAL$37,507,534100594427 2006 Investment  TYPE OF AWARD$%Number of ProjectsNumber of Projects Weighted at 100%Career/salary$18,718,46150339306Establishment$987,56533733Tier 1 CRC$11,574,0003110040Tier 2 CRC$5,383,0831411143Other chair$844,425275TOTAL$37,507,534100594427

32. 32

33. 33

34. 34 2006 Investment  TYPE OF AWARD$%Number of ProjectsNumber of Projects Weighted at 100%Career/salary$18,718,46150339306Establishment$987,56533733Tier 1 CRC$11,574,0003110040Tier 2 CRC$5,383,0831411143Other chair$844,425275TOTAL$37,507,534100594427 2006 Investment  TYPE OF AWARD$%Number of ProjectsNumber of Projects Weighted at 100%Career/salary$18,718,46150339306Establishment$987,56533733Tier 1 CRC$11,574,0003110040Tier 2 CRC$5,383,0831411143Other chair$844,425275TOTAL$37,507,534100594427 2006 Investment  TYPE OF AWARD$%Number of ProjectsNumber of Projects Weighted at 100%Career/salary$18,718,46150339306Establishment$987,56533733Tier 1 CRC$11,574,0003110040Tier 2 CRC$5,383,0831411143Other chair$844,425275TOTAL$37,507,534100594427

35. 35

36. 36

37. 37

38. 38

39. The report, Cancer Research Investment in Canada, 2018, supplementary data, and interactive dashboards are available at http://www.ccra-acrc.ca. Production of this report was made possible through collaboration and financial support from the Canadian Partnership Against Cancer Corporation and Health Canada.We would like to thank the many organizations that participate in the CCRS by contributing their data on an annual basis. Without them, this report would not have been possible. We would also like to acknowledge the experts who advised us on this report: Dr. Cindy Bell (Genome Canada), Dr. Judy Bray (Canadian Cancer Society), Dr. Jim Hudson (Consultant), Mr. Rami Rahal (Canadian Partnership Against Cancer), Dr. Stephen Robbins (CIHR Institute of Cancer Research), Dr. Sara Urowitz (Canadian Partnership Against Cancer/Canadian Cancer Research Alliance), and Dr. Christine Williams (Ontario Institute for Cancer Research). CCRA is a member of the International Cancer Research Partnership (ICRP), a group of cancer research funding organizations that agree to adhere to common classification standards and share investment data. The survey for the 2019 data year is currently underway.Questions about this project should be directed to the CCRA Program Manager at info@ccra-crc.ca.Further Information39

40. www.ccra-acrc.ca@CCRAlliancelinkedin.com/company/canadian-cancer-research-alliance/info@ccra-acrc.ca